


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 233/44, A61K 31/415, C07D 233/88		A1	(11) International Publication Number: WO 98/14432
			(43) International Publication Date: 9 April 1998 (09.04.98)
(21) International Application Number: PCT/EP97/05322		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 24 September 1997 (24.09.97)		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(30) Priority Data: 96202749.6 2 October 1996 (02.10.96) EP			
(34) Countries for which the regional or international application was filed: DE et al.			
(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).			
(72) Inventors; and (75) Inventors/Applicants (for US only): FREYNE, Eddy, Jean, Edgard [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). FERNANDEZ-GADEA, Francisco Javier [ES/ES]; Sagra No. 20, Cerro de las Perdices (Bargas), E-45593 Toledo (ES). ANDRES-GIL, José Ignacio [ES/ES]; Vesubiana No. 22, Getafe-Sector 3, B-28905 Madrid (ES).			
(74) Agent: QUAGHEBEUR, Luc; Janssen Pharmaceutica N.V., Patent Dept., Turnhoutseweg 30, B-2340 Beerse (BE).			

(54) Title: PDE IV INHIBITING 2-CYANOIMINOIMIDAZOLE DERIVATIVES



(57) Abstract

The present invention concerns 2-cyanoiminoimidazole derivatives having formula (I) the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein R^1 and R^2 each independently are hydrogen; C_{1-6} alkyl; difluoromethyl; trifluoromethyl; C_{3-6} cycloalkyl; a saturated 5-, 6- or 7-membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur or nitrogen; indanyl; 6,7-dihydro-5*H*-cyclopentapyridinyl; bicyclo[2.2.1]-2-heptenyl; bicyclo[2.2.1]heptanyl; C_{1-6} alkylsulfonyl; arylsulfonyl; or substituted C_{1-10} alkyl; R^3 is hydrogen, halo or C_{1-6} alkyloxy; R^4 is hydrogen; halo; C_{1-6} alkyl; trifluoromethyl; C_{3-6} cycloalkyl; carboxyl; C_{1-6} alkyloxycarbonyl; C_{3-6} cycloalkylaminocarbonyl; aryl; Het¹; or substituted C_{1-6} alkyl; or R^4 is $-O-R^7$ or $-NH-R^8$; R^5 is hydrogen, halo, hydroxy, C_{1-6} alkyl or C_{1-6} alkyloxy; R^6 is a hydrogen or C_{1-6} alkyl; or R^4 and R^6 , or R^4 and R^5 taken together may form a bivalent radical; $-A-B-$ is $-CR^{10}-CR^{11}-$ or $-CHR^{10}-CHR^{11}-$; L is hydrogen; C_{1-6} alkyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyloxycarbonyl; substituted C_{1-6} alkyl; C_{3-6} alkenyl; substituted C_{3-6} alkenyl; piperidinyl; substituted piperidinyl; C_{1-6} alkylsulfonyl or arylsulfonyl; having PDE IV and cytokine inhibiting activity. The invention also relates to processes for preparing the compounds of formula (I) and pharmaceutical compositions thereof.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-


PDE IV INHIBITING 2-CYANOIMINOIMIDAZOLE DERIVATIVES

5 The present invention concerns 2-cyanoiminoimidazole derivatives having phosphodiesterase IV (PDE IV) and cytokine inhibiting activity and their preparation; it further relates to compositions comprising them, as well as their use as a medicine.

10 WO 95/05386, published on February 23, 1995 by Smithkline Beecham Corporation, discloses phenethylamine derivatives, such as *N*-[2-(3-cyclopentyloxy-3-methoxyphenyl)ethyl]imidodicarbamide and *N'*-cyano-1-[2-(3-cyclopentyloxy-4-methoxyphenyl)ethyl]carboximidamide, useful for treating phosphodiesterase IV related disease states. It also generically discloses phenethylamine derivatives containing a cyanoguanidine moiety.

15 The compounds of the present invention differ structurally from art-known PDE IV inhibitors by the fact that they invariably contain a 2-cyanoiminoimidazole moiety. They have therapeutical utility in the treatment of disease states related to an abnormal enzymatic or catalytic activity of PDE IV, and/or disease states related to a
20 physiologically detrimental excess of cytokines, in particular allergic, atopic and inflammatory diseases. The present compounds also have few gastro-intestinal side-effects which are often associated with PDE IV inhibitors.

25 The present invention concerns 2-cyanoiminoimidazole derivatives having the formula



the *N*-oxide forms, the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, wherein :

30 R^1 and R^2 each independently are hydrogen; C_{1-6} alkyl; difluoromethyl; trifluoromethyl; C_{3-6} cycloalkyl; a saturated 5-, 6- or 7-membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur or nitrogen; indanyl; 6,7-dihydro-5*H*-cyclopentapyridinyl; bicyclo[2.2.1]-2-heptenyl; bicyclo[2.2.1]heptanyl; C_{1-6} alkyl-sulfonyl; arylsulfonyl; or C_{1-10} alkyl substituted with one or two substituents each independently selected from aryl, pyridinyl, thienyl, furanyl, indanyl, 6,7-dihydro-5*H*-

-2-

cyclopentapyridinyl, C₃₋₇cycloalkyl and a saturated 5-, 6- or 7-membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur or nitrogen;

R³ is hydrogen, halo or C₁₋₆alkyloxy;

5 R⁴ is hydrogen; halo; C₁₋₆alkyl; trifluoromethyl; C₃₋₆cycloalkyl; carboxyl; C₁₋₄alkyloxycarbonyl; C₃₋₆cycloalkylaminocarbonyl; aryl; Het¹; or C₁₋₆alkyl substituted with cyano, amino, hydroxy, C₁₋₄alkylcarbonylamino, aryl or Het¹; or

R⁴ is a radical of formula :

-O-R⁷ (a-1); or

-NH-R⁸ (a-2);

10 wherein R⁷ is hydrogen; C₁₋₆alkyl; C₁₋₆alkyl substituted with hydroxy, carboxyl, C₁₋₄alkyloxycarbonyl, amino, mono- or di(C₁₋₄alkyl)-amino, Het¹ or aryl;

R⁸ is hydrogen; C₁₋₆alkyl; C₁₋₄alkylcarbonyl; C₁₋₆alkyl substituted with hydroxy, carboxyl, C₁₋₄alkyloxycarbonyl, amino, mono- or di(C₁₋₄alkyl)amino, Het¹ or aryl;

15

R⁵ is hydrogen, halo, hydroxy, C₁₋₆alkyl or C₁₋₆alkyloxy; or

R⁴ and R⁵ taken together may form a bivalent radical of formula :

-(CH₂)_n- (b-1);

-CH₂-CH₂-O-CH₂-CH₂- (b-2);

20 -CH₂-CH₂-N(R⁹)-CH₂-CH₂- (b-3); or

-CH₂-CH=CH-CH₂- (b-4);

wherein n is 2, 3, 4 or 5;

R⁹ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylsulfonyl or *p*-toluenesulfonyl;

R⁶ is a hydrogen or C₁₋₄alkyl; or

25 R⁴ and R⁶ taken together may form a bivalent radical of formula -(CH₂)_m-;

wherein m is 1, 2, 3 or 4;

-A-B- is a bivalent radical of formula :

-CR¹⁰=CR¹¹- (c-1); or

-CHR¹⁰-CHR¹¹- (c-2);

30 wherein each R¹⁰ and R¹¹ independently is hydrogen or C₁₋₄alkyl; and

L is hydrogen; C₁₋₆alkyl; C₁₋₆alkylcarbonyl; C₁₋₆alkyloxycarbonyl; C₁₋₆alkyl substituted with one or two substituents selected from the group consisting of hydroxy, C₁₋₄alkyloxy, C₁₋₄alkyloxycarbonyl, mono- and di(C₁₋₄alkyl)amino, aryl and Het²; C₃₋₆alkenyl; C₃₋₆alkenyl substituted with aryl; piperidinyl; piperidinyl substituted with C₁₋₄alkyl or aryl; C₁₋₄alkyl; C₁₋₆alkylsulfonyl or arylsulfonyl;

35

-3-

aryl is phenyl or phenyl substituted with one, two or three substituents selected from halo, hydroxy, C₁₋₄alkyl, C₁₋₄alkyloxy, C₃₋₆cycloalkyl, trifluoromethyl, amino, nitro, carboxyl, C₁₋₄alkyloxycarbonyl and C₁₋₄alkylcarbonylamino;

5 Het¹ is pyridinyl; pyridinyl substituted with C₁₋₄alkyl; furanyl; furanyl substituted with C₁₋₄alkyl; thienyl; thienyl substituted with C₁₋₄alkylcarbonylamino; hydroxypyridinyl, hydroxypyridinyl substituted with C₁₋₄alkyl or C₁₋₄alkoxy-C₁₋₄alkyl; imidazolyl; imidazolyl substituted with C₁₋₄alkyl; thiazolyl; thiazolyl substituted with C₁₋₄alkyl; oxazolyl; oxazolyl substituted with C₁₋₄alkyl; isoquinolinyl; isoquinolinyl substituted with C₁₋₄alkyl; quinolinonyl, 10 quinolinonyl substituted with C₁₋₄alkyl; morpholinyl; piperidinyl; piperidinyl substituted with C₁₋₄alkyl, C₁₋₄alkyloxycarbonyl or arylC₁₋₄alkyl; piperazinyl; piperazinyl substituted with C₁₋₄alkyl, C₁₋₄alkyloxycarbonyl or arylC₁₋₄alkyl; and

15 Het² is morpholinyl; piperidinyl; piperidinyl substituted with C₁₋₄alkyl or aryl-C₁₋₄alkyl; piperazinyl; piperazinyl substituted with C₁₋₄alkyl or arylC₁₋₄alkyl; pyridinyl; pyridinyl substituted with C₁₋₄alkyl; furanyl; furanyl substituted with C₁₋₄alkyl; thienyl or thienyl substituted with C₁₋₄alkyl or C₁₋₄alkylcarbonyl-amino.

20 Some of the compounds of formula (I) may also exist in their tautomeric forms. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention. In particular, compounds of formula (I) wherein L is hydrogen may exist in their corresponding tautomeric form.

25 In R¹ and R², the saturated 5-, 6- or 7-membered heterocycles containing one or two heteroatoms selected from oxygen, sulfur or nitrogen may suitably be selected from heterocycles such as, for example, tetrahydrofuranyl, dioxolanyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl and tetrahydropyranyl. Said heterocyclic radicals are attached to the oxygen atom or the C₁₋₁₀alkyl radical by any carbon atom or, where 30 appropriate, by a nitrogen atom.

Also in R¹ and R², the term 6,7-dihydro-5*H*-cyclopentapyridinyl, also named 6,7-dihydro-5*H*-pyrindinyl, is meant to represent 6,7-dihydro-5*H*-cyclopenta[b]pyridine or 6,7-dihydro-5*H*-cyclopenta[c]pyridinyl and may be attached to the remainder of the 35 molecule by any of the aliphatic or aromatic carbon atoms.

As used herein the term halo is generic to fluoro, chloro, bromo and iodo; the term C₁₋₄alkyl is meant to include straight chained or branched saturated hydrocarbons

-4-

- having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, 1-methylethyl, 1,1-dimethylethyl, propyl, 2-methylpropyl and butyl; the term C₁₋₆alkyl is meant to include C₁₋₄alkyl and the higher homologues thereof having 5 or 6 carbon atoms such as, for example, 2-methylbutyl, pentyl, hexyl and the like; the term C₁₋₆alkyl is meant to include C₂₋₆alkyl and the lower homologue thereof having 1 carbon atom such as, for example, methyl; C₁₋₁₀alkyl is meant to include C₁₋₆alkyl and the higher homologues thereof having from 7 to 10 carbon atoms such as, for example, heptyl, octyl, nonyl, decyl, 1-methylhexyl, 2-methylheptyl and the like; the term C₃₋₆alkenyl defines straight and branch chained hydrocarbon radicals containing one double bond and having from 3 to 6 carbon atoms such as, for example, 2-propenyl, 3-butenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl and the like; and the carbon atom of said C₃₋₆alkenyl being connected to a nitrogen atom preferably is saturated; the term C₃₋₆cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; the term C₃₋₇cycloalkyl is meant to include C₃₋₆cycloalkyl and cycloheptyl; the term C₁₋₄alkanediyl is meant to include straight chained and branched saturated bivalent hydrocarbon radicals having from 1 to 4 carbon atoms, such as, for example, methylene, 1,2-ethanediyl, 1,1-ethanediyl, 1,3-propanediyl, 1,2-propanediyl, 1,4-butanediyl, 2-methyl-1,3-propanediyl and the like.
- As used in the foregoing definitions and hereinafter, haloC₁₋₄alkanediyl is defined as mono- or polyhalosubstituted C₁₋₄alkanediyl, in particular C₁₋₄alkanediyl substituted with one or more fluor atoms.

- The pharmaceutically acceptable acid addition salts as mentioned hereinabove are meant to comprise the acid addition salt forms which can conveniently be obtained by treating the base form of the compounds of formula (I) with appropriate acids such as inorganic acids, for example, hydrohalic acid, e.g. hydrochloric or hydrobromic, sulfuric, nitric, phosphoric and the like acids; or organic acids, such as, for example, acetic, hydroxy-acetic, propanoic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-aminosalicylic, pamoic and the like acids. Conversely, said acid addition salt forms can be converted in the free base forms by treatment with an appropriate base.
- The compounds of formula (I) containing an acidic proton may also be converted into their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium,

-5-

potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, *N*-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.

- 5 The term addition salt also comprises the hydrates and solvent addition forms which the compounds of formula (I) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.

- 10 The *N*-oxide forms of the compounds of formula (I) are meant to comprise those compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the so-called *N*-oxide.

- 15 The term "stereochemically isomeric forms" as used hereinbefore defines all the possible isomeric forms which the compounds of formula (I) may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure. More in particular, stereogenic centers may have the *R*- or *S*-configuration, and the =*N*-CN and substituted C₃₋₆alkenyl moieties may have the *E*- or *Z*-configuration.

- 20 Whenever used hereinafter, the term compounds of formula (I) is meant to include also the *N*-oxide forms, the pharmaceutically acceptable acid or base addition salts and all stereoisomeric forms.

- 25 Some of the compounds of formula (I) and some of the intermediates in the present invention may contain an asymmetric carbon atom. Pure stereochemically isomeric forms of said compounds and said intermediates can be obtained by the application of art-known procedures. For example, diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter
30 current distribution, liquid chromatography and the like methods. Enantiomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or compounds by, for example, selective crystallization or chromatographic techniques,
35 e.g. liquid chromatography and the like methods; and finally converting said separated diastereomeric salts or compounds into the corresponding enantiomers. Pure stereochemically isomeric forms may also be obtained from the pure stereochemically isomeric forms of the appropriate intermediates and starting materials, provided that the

-6-

intervening reactions occur stereospecifically. The pure and mixed stereochemically isomeric forms of the compounds of formula (I) are intended to be embraced within the scope of the present invention.

- 5 An alternative manner of separating the enantiomeric forms of the compounds of formula (I) and intermediates involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase.

- 10 A special group of compounds includes those compounds of formula (I) wherein R^1 and R^2 each independently are hydrogen; C_{1-6} alkyl; difluoromethyl; trifluoromethyl; C_{3-6} cycloalkyl; a saturated 5-, 6- or 7-membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur or nitrogen; indanyl; bicyclo[2.2.1]-2-heptenyl; bicyclo[2.2.1]heptanyl; C_{1-6} alkylsulfonyl; arylsulfonyl; or C_{1-10} alkyl substituted with one or two substituents each independently selected from aryl, 15 pyridinyl, thienyl, furanyl, C_{3-7} cycloalkyl and a saturated 5-, 6- or 7-membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur or nitrogen.

- 20 Interesting compounds are those compounds of formula (I) wherein R^1 and R^2 are each independently C_{1-6} alkyl; C_{3-6} cycloalkyl; difluoromethyl; a saturated 5-, 6- or 7-membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur or nitrogen, which preferably is tetrahydrofuranyl; indanyl; or C_{1-10} alkyl substituted with aryl, indanyl, 6,7-dihydro-5H-cyclopentapyridinyl or C_{3-6} cycloalkyl.

- 25 Also interesting are those compounds of formula (I) wherein R^5 is hydrogen and R^4 is hydrogen, hydroxy or C_{1-6} alkyl, more in particular, R^4 is methyl.

- 30 Another interesting group are those compounds of formula (I) wherein L is hydrogen, C_{1-6} alkyloxycarbonyl, or C_{1-6} alkyl substituted with one or two phenyl rings.

- Particular compounds are those compounds of formula (I) wherein R^1 is cyclopentyl, tetrahydrofuranyl, cyclopropylmethyl, 5-phenylpentyl, 2-indanylethyl, 6,7-dihydro-5H-cyclopenta[b]pyridinyl or indanyl; and R^2 is methyl or difluoromethyl.

- 35 Preferred compounds are those particular compounds wherein R^3 , R^5 , R^6 , R^{10} , R^{11} and L are hydrogen.

Most preferred are the following compounds :

-7-


[1-[2-[4-(difluoromethoxy)-3-[(tetrahydro-3-furanyl)oxy]phenyl]propyl]-1,3-dihydro-2H-imidazol-2-ylidene]cyanamide; and

[1-[2-[4-(methoxy)-3-[(1,3-dihydro-2H-inden-2-yl)oxy]phenyl]propyl]-1,3-dihydro-2H-imidazol-2-ylidene]cyanamide; their *N*-oxides, their stereochemically isomeric

5 forms and their pharmaceutically acceptable additon salts.

Whenever used hereinafter, R^1 to R^{11} , Y, -A-B- and L are defined as under formula (I) unless otherwise indicated.

- 10 Compounds of formula (I) wherein -A-B- is a radical of formula (c-1) and L is hydrogen, said compounds being represented by formula (I-a-1), can conveniently be prepared by cyclization of an intermediate of formula (II) or a functional derivative thereof in the presence of a suitable acid such as, for example, hydrochloric acid.




- 15 Said cyclization may be performed in a reaction inert solvent such as, for example, tetrahydrofuran or 1,4-dioxane or a mixture thereof. Stirring and heating may enhance the rate of the reaction.


- 20 In this and the following preparations, the reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art such as, for example, extraction, crystallization, trituration and chromatography.

- 25 In particular, compounds of formula (I-a-1) wherein R^5 is hydroxy, said compounds being represented by formula (I-a-1-1), may be prepared by cyclization of an intermediate of formula (II-1) wherein P is hydrogen or, preferably, is a trimethylsilyl protecting group or a functional derivative thereof, in a manner analogous to the one described for the preparation of a compound of formula (I-a-1) from an intermediate of formula (II).


-8-



- Compounds of formula (I) wherein -A-B- is a radical of formula (c-2) and L is hydrogen, said compounds being represented by formula (I-a-2), can be obtained by cyclization of an intermediate of formula (III) or a functional derivative thereof in the presence of a suitable reagent such as, for example, dimethyl cyanocarbonimido-dithioate or diphenyl *N*-cyanocarbonimide.



- Alternatively, compounds of formula (I) may be prepared by reacting an organometallic intermediate of formula (IV), wherein M is an appropriate metal ion or metalcomplex ion such as, for example, Li^+ , $(\text{MgBr})^+$, $\text{B}(\text{OH})_2^+$ or $\text{Sn}(\text{CH}_3)_3^+$, in a reaction-inert solvent with a suitable 2-cyanoiminoimidazole derivative of formula (V) wherein W^1 is a reactive leaving group such as, for example, a halogen. In case R^4 and R^5 are taken together and form a radical of formula (b-1), (b-2), (b-3) or (b-4), W^1 may also be a cyanide moiety provided that the intermediate of formula (IV) is a Grignard reagent.




Said reaction may be performed in a reaction-inert solvent such as, for example, dimethoxyethane, tetrahydrofuran or diethylether. Stirring and heating may enhance the rate of the reaction. In case intermediates of formula (V), wherein L is replaced by a suitable protecting group, are used in said reaction, compounds of formula (I) wherein

L is hydrogen, said compounds being represented by compounds of formula (I-a), may be obtained using art-known deprotection reactions.

The compounds of formula (I) can also be converted into each other following art-known procedures of functional group transformation.

For example, compounds of formula (I) wherein L is other than hydrogen, said compounds being represented by formula (I-b), may be prepared by reacting a compound of formula (I-a) with L'-W² (VI), wherein L' is the same as L defined under formula (I) but other than hydrogen and W² is a reactive leaving group such as, for example, a halogen atom.



Also art-known addition reactions may be used to convert compounds of formula (I-a) into compounds of formula (I-b).


The compounds of formula (I) may also be converted to the corresponding *N*-oxide forms following art-known procedures for converting a trivalent nitrogen into its *N*-oxide form. Said *N*-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with 3-phenyl-2-(phenylsulfonyl)oxaziridine or with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarboperoxoic acid, peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. *t*-butyl hydroperoxide. Suitable solvents are, for example, water, lower alkanols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.

Intermediates mentioned hereinabove may be prepared following art-known techniques.

In particular, intermediates of formula (II) may be prepared by first reacting an amine of formula (VII) with dimethyl cyanocarbonimidodithioate or diphenyl cyanocarbonimidate or a functional derivative thereof. Said reaction can conveniently be


-10-

performed in a reaction inert solvent such as, for example, dichloromethane, benzene or toluene, optionally cooled on an ice-bath, and in the presence of a base such as, for example, *N,N*-diethylethanamine or sodiumbicarbonate. The thus obtained intermediate may be subsequently reacted with an intermediate of formula (VIII) or a functional derivative thereof, to form an intermediate of formula (II). Said reaction can conveniently be performed in a reaction inert solvent such as, for example, 1,4-dioxane, in the presence of a base such as, for example, *N,N*-diethylethanamine, and optionally in the presence of a catalyst such as, for example, *N,N*-dimethyl-pyridinamine. Stirring and elevated temperatures may enhance the rate of the reaction.



Alternatively, the above reaction may be performed in reverse order, i.e. first react an intermediate of formula (VIII) with dimethyl cyanocarbonimidodithioate or diphenyl cyanocarbonimidate or a functional derivative thereof, and subsequently react the thus formed intermediate with an amine of formula (VII).


15
20
Intermediates of formula (III) wherein R¹¹ is hydrogen, said intermediates being represented by formula (III-1), may be prepared by first reacting an amine of formula (VII) with a cyano derivative of formula (IX) wherein W³ is an appropriate leaving group such as, for example, a halogen, in the presence of a base such as, for example, sodiumcarbonate, in a reaction-inert solvent such as, for example, *N,N*-dimethyl-formamide. Subsequently, the cyanide moiety in the thus formed intermediate may be reduced using a suitable reducing agent such as, for example, lithium aluminium hydride or hydrogen in the presence of a catalyst such as, for example, Raney nickel, thus obtaining an intermediate of formula (III-1).




Some of the intermediates of formula (VII) are described in WO 92/00968, WO 93/15044 and WO 93/15045.

-11-

- In particular, intermediates of formula (VII) may be prepared by reacting an intermediate of formula (X) wherein W^4 is a suitable leaving group such as, for example, a halogen with an intermediate of formula (XI) wherein M is an appropriate metal ion or metalcomplex ion such as, for example, Li^+ or $(MgBr)^+$, and P is a suitable protecting group such as, for example, (1,1-dimethylethyl)oxycarbonyl. The thus obtained protected intermediates of formula (VII) may subsequently be deprotected by art-known techniques such as, for example, acid hydrolysis.




- Intermediates of formula (VII) wherein R^6 is hydrogen, said intermediates being represented by formula (VII-1), may be prepared by reducing the unsaturated carbon-nitrogen bond in the intermediates of formula (XII) with a suitable reducing agent such as, for example, borane-tetrahydrofuran-complex, lithium aluminium hydride, or hydrogen in the presence of a catalyst such as, for example, Raney nickel. The cyanide moiety in the intermediates of formula (XII) may also be replaced by a functional derivative thereof such as, for example, an oxime moiety.



Some of the intermediates of formula (XII) are described in WO 92/00968, WO 93/15044 and WO 93/15045.

- In particular, intermediates of formula (XII) wherein R^5 is a protected hydroxy group and R^4 is hydrogen, said intermediates being represented by formula (XII-1), can conveniently be prepared by reacting an aldehyde of formula (XIII) with a reagent of formula (XIV) or a functional derivative thereof wherein P is a protective group such as, for example, trimethylsilyl and the like, in a reaction-inert solvent such as, for example, dichloromethane, and in the presence of a catalytic amount of ZnI_2 or a functional derivative thereof. Said intermediates of formula (XII-1) may be further reacted as described hereinabove to finally form a compound of formula (I) wherein R^5 is hydroxy.

-12-



The aldehydes of formula (XIII) can conveniently be prepared analogous to the reaction procedure described by Mitsunobu Oyo in *Synthesis*, 1-28, 1981.

- 5 Some of the compounds of formula (I) and some of the intermediates in the present invention contain at least one asymmetric carbon atom. Pure stereochemically isomeric forms of said compounds and said intermediates can be obtained by the application of art-known procedures. For example, diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter
- 10 current distribution, liquid chromatography and the like methods. Enantiomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or compounds by, for example, selective crystallization or chromatographic techniques,
- 15 e.g. liquid chromatography and the like methods; and finally converting said separated diastereomeric salts or compounds into the corresponding enantiomers.

Pure stereochemically isomeric forms of the compounds of formula (I) may also be obtained from the pure stereochemically isomeric forms of the appropriate inter-

20 mediates and starting materials, provided that the intervening reactions occur stereospecifically. The pure and mixed stereochemically isomeric forms of the compounds of formula (I) are intended to be embraced within the scope of the present invention.

The compounds of formula (I), the *N*-oxide forms, pharmaceutically acceptable acid or

25 base addition salts and the stereochemically isomeric forms thereof, are potent inhibitors of the phosphodiesterase (PDE) isoenzymes of family IV (cAMP-specific family).

cAMP (adenosine cyclic 3',5'-monophosphate) is a key second messenger, the

30 concentration of which affects particular cell activities through activation of enzymes such as kinases. PDE IV is known to hydrolyse cAMP to its corresponding inactive 5'-monophosphate metabolite. Hence, inhibition of PDE IV leads to an elevation of cAMP levels in particular cells such as the respiratory smooth muscle cell and in a wide variety of inflammatory cells, i.e. certain lymphocytes, e.g. basophils, neutrophils and

-13-

eosinophils, monocytes and mast-cells. A number of allergic, atopic and inflammatory diseases are deemed to be caused by higher-than-normal PDE IV concentrations which result in low cAMP levels and hypersensitivity of the thus affected cells for excitatory stimuli. (Examples of said hypersensitivity are for example, excessive histamine
5 release from basophils and mast cells or excessive superoxide anion radical formation by eosinophils.) Hence, the present compounds having potent phosphodiesterase IV inhibitory properties are deemed useful agents in alleviating and/or curing allergic, atopic and inflammatory diseases. The functional effects of PDE IV inhibitors are e.g. respiratory smooth muscle relaxation, bronchodilation, platelet aggregation inhibition
10 and inhibition of white blood cell mediator release. Examples of allergic diseases are bronchial asthma, cheilitis, conjunctivitis, contact dermatitis and eczema, irritable bowel disease, deshydroform eczema, urticaria, vasculitis, vulvitis; examples of atopic diseases are dermatitis and eczema, winterfct, asthma, allergic rhinitis; and related afflictions are, for example, psoriasis and other hyperproliferative diseases.

15 The present invention thus also relates to compounds of formula (I) as defined hereinabove for use as a medicine, in particular for use as a medicine for treating atopic diseases or as an anti-asthmatic medicine. Thus the compounds of the present invention may be used for the manufacture of a medicament for treating atopic or
20 asthmatic diseases, more in particular atopic dermatitis.

The PDE IV inhibitory activity of the compounds of formula (I) may be demonstrated in the test "Inhibition of recombinant human mononuclear lymphocyte (MNL) phosphodiesterase type IV B produced in insect cells with a baculovirus vector".
25 Several *in vivo* and *in vitro* tests may be used to demonstrate the usefulness of the compounds of formula (I) in treating the described allergic, atopic and inflammatory diseases. Such tests are for instance, "Bronchoconstriction of the guinea pig trachea *in vitro*", "Bronchoconstriction of the guinea pig trachea *in vivo*" and the *in vivo* tests "Arachidonic acid induced pinnal inflammation in mice", "TPA induced ear
30 inflammation in mice", and "Delayed type hypersensitivity in mice".

Further, the present compounds have only very low inhibitory activity on the phosphodiesterase isoenzymes of family III (cGMP-inhibited family). Inhibition of, in particular, PDE III leads to an elevation of cAMP in the cardiac muscle, thereby
35 causing effects on the contractile force of the heart as well as on the relaxation of the heart. In the treatment of the described allergic, atopic and inflammatory diseases, cardiovascular effects clearly are undesired. Hence, as the present compounds inhibit

PDE IV at much lower concentrations as they inhibit PDE III, their therapeutic use may be adjusted to avoid cardiovascular side-effects.

Art-known PDE IV inhibitors often cause adverse gastro-intestinal side effects. Most
5 of the present compounds, however, have few effects on the gastro-intestinal tract,
which may be demonstrated in the test "Gastric emptying of a caloric meal in rats".

The designation PDE III and IV as used herein refers to the classification by J. A.
Beavo and D. H. Reifsnnyder, TIPS Reviews, April 1990, pp. 150-155.

10 The compounds of the present invention also have cytokine inhibitory activity. A
cytokine is any secreted polypeptide that affects the function of other cells by
modulating interactions between cells in the immune or inflammatory response.
Examples of cytokines are monokines and lymphokines and they may be produced by a
15 wide variety of cells. For instance, a monokine is generally referred to as being
produced and secreted by a mononuclear cell, such as a macrophage and/or monocyte
but many other cells produce monokines, such as natural killer cells, fibroblasts,
basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells,
epidermal keratinocytes, and β -lymphocytes. Lymphokines are generally referred to as
20 being produced by lymphocyte cells. Examples of cytokines include Interleukin-1
(IL-1), Interleukin-2 (IL-2), Interleukin-6 (IL-6), Interleukin-8 (IL-8), alpha-Tumor
Necrosis Factor (α TNF) and beta-Tumor Necrosis Factor (β TNF).

The cytokine specifically desired to be inhibited is α TNF. Excessive or unregulated
25 TNF production is implicated in mediating or exacerbating a number of diseases
including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis,
and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative
sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria,
chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone
30 resorption diseases, reperfusion injury, graft versus host reaction, allograft rejections,
fever and myalgias due to infection, such as influenza, cachexia secondary to infection
or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS),
AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's
disease, ulcerative colitis, or pyresis.

35 The cytokine inhibitory activity of the compounds of formula (I), such as the inhibition
of α TNF production, may be demonstrated in the *in vitro* test "Cytokine production in
human whole blood cultures".

In addition, the compounds of the present invention are expected to show no or little endocrinological side-effects. This may be evidenced by, for instance, the "Testosterone *in vivo*" test, the "*In vitro* inhibition of the aromatase activity"-test and the "*In vivo* inhibition of the aromatase activity"-test.

5 In view of their useful PDE IV and cytokine inhibiting properties, the subject compounds may be formulated into various pharmaceutical compositions for administration purposes comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound of formula (I). To prepare
10 the pharmaceutical compositions of this invention, a therapeutically effective amount of the particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage
15 form suitable, preferably, for administration orally, rectally, topically, percutaneously, by inhalation or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as
20 starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part,
25 though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous
30 administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause any significant deleterious effects on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be
35 administered in various ways, e.g., as a transdermal patch, as a spot-on or as an ointment. As appropriate compositions for topical application there may be cited all compositions usually employed for topically administering drugs e.g. creams, gellies,

-16-

dressings, shampoos, tinctures, pastes, ointments, salves, powders and the like.

Application of said compositions may be by aerosol, e.g. with a propellant such as nitrogen, carbon dioxide, a freon, or without a propellant such as a pump spray, drops, lotions, or a semisolid such as a thickened composition which can be applied by a swab. In particular, semisolid compositions such as salves, creams, gellies, ointments and the like will conveniently be used.

In order to enhance the solubility and/or the stability of the compounds of formula (I) in pharmaceutical compositions, it can be advantageous to employ α -, β - or γ -cyclodextrins or their derivatives, in particular hydroxyalkyl substituted cyclodextrins, e.g. 2-hydroxypropyl- β -cyclodextrin. Also co-solvents such as alcohols may improve the solubility and/or the stability of the compounds of formula (I) in pharmaceutical compositions. In the preparation of aqueous compositions, addition salts of the subject compounds are obviously more suitable due to their increased water solubility.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions and the like, and segregated multiples thereof.

The present invention also relates to a method of treating warm-blooded animals suffering from disease states related to an abnormal enzymatic or catalytic activity of PDE IV, and/or disease states related to a physiologically detrimental excess of cytokines, in particular allergic, atopic and inflammatory diseases, more in particular asthmatic and atopic diseases, most particular atopic dermatitis. Said method comprises the administration of a therapeutically effective amount of a compound of formula (I) or a *N*-oxide form, a pharmaceutically acceptable acid or base addition salt or a stereochemically isomeric form thereof in admixture with a pharmaceutical carrier.

In general it is contemplated that an effective daily amount would be from 0.01 mg/kg to 10 mg/kg body weight. It is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The

-17-

effective daily amount range mentioned hereinabove are therefore guidelines only and are not intended to limit the scope or use of the invention to any extent.

5 The following examples are intended to illustrate and not to limit the scope of the present invention.

Experimental part

10 Of some compounds of formula (I) the absolute stereochemical configuration was not experimentally determined. In those cases the stereochemically isomeric form which was first isolated is designated as "A" and the second as "B", without further reference to the actual stereochemical configuration.

15 Hereinafter, "THF" means tetrahydrofuran, "RT" means room temperature, "DMF" means *N,N*-dimethylformamide and "DIPE" means diisopropylether.

A. Preparation of the intermediate compounds

Example A.1

20 a) Potassium carbonate (0.0569 mol) was added dropwise to a mixture of 4-difluoromethoxy-3-hydroxybenzaldehyde (0.053 mol) and (tetrahydro-3-furanol)-4-methylbenzenesulfonate (15.35 g) in DMF (100 ml) under N₂ flow. The reaction mixture was stirred for 4 hours at 100 °C. The mixture was cooled and a solution of (tetrahydro-3-furanol)-4-methylbenzenesulfonate (3.98 g) in DMF (40 ml) was added dropwise and the reaction mixture was stirred for 3 hours at 100 °C, then overnight at RT. The solvent was evaporated and the residue was washed in a saturated aqueous Na₂CO₃ solution, then extracted with DIPE. The separated organic layer was dried, filtered, and the solvent was evaporated, yielding 17.77 g of (±)-4-(difluoromethoxy)-3-[(tetrahydro-3-furanyl)oxy]benzaldehyde (intermediate 1).

30 b) A sodium borohydride solution (0.0177 mol) was added portionwise to a solution of intermediate 1 (0.0532 mol) in methanol (100 ml), and the reaction mixture was stirred for 1 hour at RT. The solvent was evaporated, the residue was washed with water, and extracted with CH₂Cl₂. The separated organic layer was dried, filtered, and the solvent was evaporated. The residue was purified by open column chromatography over silica gel (eluent: CH₂Cl₂/2-propanone 96/4 and 90/10; CH₂Cl₂/CH₃OH 96/4). The pure fractions were collected and the solvent was evaporated, yielding 11.3 g (81%) of (±)-4-(difluoromethoxy)-3-[(tetrahydro-3-furanyl)oxy]benzenemethanol (intermediate 2).

35 c) A solution of intermediate 2 (0.039 mol) in toluene (45 ml) was added dropwise to a mixture of SOCl₂ (0.059 mol) and DMF (0.0019 mol) in toluene (75 ml), stirred at

-18-

- 40°C. The resulting reaction mixture was stirred at 40 °C, until HCl-gas evolution had stopped. The solvent was evaporated and the residue was washed with a saturated aqueous NaHCO₃ solution, and extracted with CH₂Cl₂. The separated organic layer was dried, filtered, and the solvent evaporated, yielding 10.59 g (96%) of (±)-4-(difluoromethoxy)-3-[(tetrahydro-3-furanyl)oxy]benzenemethanol (intermediate 3).
- 5 d) A mixture of KCN (0.076 mol) in H₂O (4 ml), heated to 80 °C, was added dropwise to a mixture of intermediate 3 (0.038 mol) in DMF (82.4 ml), stirred at 60°C. The resulting reaction mixture was stirred for 30 minutes at 60 °C. The reaction mixture was cooled, washed with water, extracted with DIPE. The extract was dried, filtered, and the filtrate was evaporated, yielding 8.23 g (80%) of (±)-4-(difluoromethoxy)-3-[(tetrahydro-3-furanyl)oxy]benzeneacetonitrile (intermediate 4).
- 10

In a similar way, there were prepared :

- 3-(cyclopropylmethoxy)-4-methoxybenzeneacetonitrile (intermediate 5);
- 15 3-[(1,3-dihydro-2H-inden-2-yl)oxy]-4-methoxybenzeneacetonitrile (intermediate 6);
(±)-4-methoxy-3-[(tetrahydro-3-furanyl)oxy]benzeneacetonitrile (intermediate 7);
4-methoxy-3-[(5-phenylpentyl)oxy]benzeneacetonitrile (intermediate 8);
4-(difluoromethoxy)-3-[(5-phenylpentyl)oxy]benzeneacetonitrile (intermediate 23).

Example A.2

- 20 a) *N*-(1-methylethyl)-2-propanamine lithium salt (0.0325 mol; 1 M in THF) was added dropwise and under N₂ flow to intermediate 4 (0.0309 mol) in THF (70 ml), cooled to -78 °C. The mixture was stirred for 30 minutes at -78°C. Iodomethane iodide (0.034 mol) was added dropwise and the reaction mixture was stirred for 2 hours at RT. The mixture was quenched with a saturated aqueous NH₄Cl solution, and extracted
- 25 with ethylacetate. The separated organic layer was dried, filtered, and the solvent was evaporated. The residue was purified by short open column chromatography over silica gel (eluent: CH₂Cl₂), then by HPLC over silica gel (eluent: hexane/ethylacetate 3/2). The pure fractions were collected and the solvent, yielding 4.64 g (53%) of (±)-4-(difluoromethoxy)-α-methyl-3-[(tetrahydro-3-furanyl)oxy]benzene-
- 30 acetonitrile (intermediate 9).
- b) A mixture of intermediate 9 (0.0129 mol) in CH₃OH/NH₃ (100 ml) was hydrogenated at RT with Raney Nickel (3 g) as a catalyst. After uptake of H₂, the catalyst was filtered off and the filtrate was evaporated, yielding 3.66 g (98%) of (±)-4-(difluoromethoxy)-β-methyl-3-[(tetrahydro-3-furanyl)oxy]benzeneethanamine
- 35 (intermediate 10).
- c) A mixture of intermediate 10 (0.0158 mol) and diphenyl *N*-cyano-carbonimidate (0.0158 mol) in ethanol (60 ml) was stirred overnight at RT. The solvent was

evaporated and the residue was purified by open column chromatography over silica gel (eluent: hexane/ethylacetate 3/2 and CH₂Cl₂/CH₃OH 96/4, 90/10 and 85/5). The pure fractions were collected and the solvent was evaporated, yielding 5.11 g (74%) of (±)-phenyl *N*-cyano-*N*-[2-[4-(difluoromethoxy)-3-[(tetrahydro-3-furanyl)oxy]-phenyl]propyl]carbamimidate (intermediate 11).

- 5 d) A mixture of 2,2-dimethoxyethanamine (0.0129 mol), *N,N*-diethylethanamine (0.023 mol) and *N,N*-dimethyl-4-pyridinamine (0.0059 mol) in 1,4-dioxane (30 ml) was added to a solution of intermediate 11 (0.0117 mol) in 1,4-dioxane (10 ml), stirred at RT. The reaction mixture was stirred and refluxed overnight. The solvent was
 10 evaporated and the residue was washed with water and 1 N NaOH, then extracted with CH₂Cl₂. The separated organic layer was dried, filtered, and the solvent was evaporated. The residue was purified by open column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 96/4). The pure fractions were collected and the solvent was evaporated, yielding 4.97 g (95%) of (±)-*N*"-cyano-*N*-[2-[4-(difluoromethoxy)-3-
 15 [(tetrahydro-3-furanyl)oxy]phenyl]propyl]-*N'*-(2,2-dimethoxyethyl)guanidine (intermediate 12).

In a similar way, there were prepared :

- (±)-*N*"-cyano-*N*-[2-[3-(cyclopentyloxy)-4-methoxyphenyl]propyl]-*N'*-(2,2-dimethoxy-
 20 ethyl)guanidine (intermediate 13);
 (±)-*N*"-cyano-*N*-[2-[3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl]propyl]-*N'*-(2,2-dimethoxyethyl)guanidine (intermediate 14);
N"-cyano-*N*-[2-[3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl]ethyl]-*N'*-(2,2-dimethoxyethyl)guanidine (intermediate 15);
 25 (±)-*N*"-cyano-*N*-[2-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]propyl]-*N'*-(2,2-dimethoxyethyl)guanidine (intermediate 16);
 (±)-*N*"-cyano-*N*-[2-[3-[(1,3-dihydro-2*H*-inden-2-yl)oxy]-4-methoxyphenyl]propyl]-*N'*-(2,2-dimethoxyethyl)guanidine (intermediate 17);
 (±)-*N*"-cyano-*N*-[2-[3-(cyclopropylmethoxy)-4-methoxyphenyl]propyl]-*N'*-(2,2-dimethoxyethyl)guanidine (intermediate 18);
 30 (±)-*N*"-cyano-*N*-(2,2-dimethoxyethyl)-*N'*-[2-[4-methoxy-3-[(5-phenylpentyl)oxy]-phenyl]propyl]guanidine (intermediate 19);
 (±)-*N*"-cyano-*N*-(2,2-dimethoxyethyl)-*N'*-[2-[4-methoxy-3-[(tetrahydro-3-furanyl)-oxy]phenyl]propyl]guanidine (intermediate 20);
 35 *N*"-cyano-*N'*-(2,2-dimethoxyethyl)-*N*-[2-[4-(difluoromethoxy)-3-[(5-phenylpentyl)-oxy]phenyl]propyl]guanidine (intermediate 24);

-20-

N''-cyano-*N'*-[2-[3-[(2,3-dihydro-1*H*-inden-2-yl)oxy]-4-methoxyphenyl]ethyl]-*N*-(2,2-dimethoxyethyl)guanidine (intermediate 25).

(±)-*N''*-cyano-*N*-[2-[3-[2-(2,3-dihydro-1*H*-inden-2-yl)ethoxy]-4-methoxyphenyl]-propyl]-*N*-(2,2-dimethoxyethyl)guanidine (intermediate 27);

- 5 (±)-*N''*-cyano-*N*-[2-[3-[(2,3-dihydro-1*H*-inden-2-yl)oxy]-4-methoxyphenyl]-2-[(tetrahydro-2*H*-pyran-2-yl)oxy]ethyl]-*N*-(2,2-dimethoxyethyl)guanidine (intermediate 28).

Example A.3

- a) A mixture of (±)-3-(cyclopentyloxy)-4-methoxy-β-methylbenzeneethanamine (0.029 mol), chloroacetonitrile (0.0146 mol) and sodium carbonate (0.0219 mol) in
10 DMF (200 ml) was stirred for 5 hours at 60 °C. The reaction mixture was filtered and the filtrate was evaporated. The residue was washed with water, then extracted with 2-methoxy-2-methylpropane. The separated organic layer was dried, filtered, and the solvent was evaporated. The residue was purified by open column chromatography over silica gel (eluent: CH₂Cl₂; CH₂Cl₂/2-propanone 96/4, and 90/10; then, CH₂Cl₂/CH₃OH
15 80/20). The pure fractions were collected and the solvent was evaporated, yielding 3.24 g (77%) of (±)-[[2-[3-(cyclopentyloxy)-4-methoxyphenyl]propyl]amino]acetonitrile (intermediate 21).

- b) A mixture of intermediate 21 (0.0117 mol) in NH₃/CH₃OH (60 ml) was hydrogenated at RT with Raney Nickel (2 g) as a catalyst. After uptake of H₂, the
20 catalyst was filtered off and the filtrate was evaporated. The residue was treated with a 10% aqueous HCl solution, and this mixture was extracted with ethylacetate. The layers were separated. The aqueous phase was basified, then extracted with ethylacetate. The separated organic layer was dried, filtered, and the solvent was evaporated, yielding 2.71 g (75%) of (±)-*N*-[2-[3-(cyclopentyloxy)-4-methoxyphenyl]propyl]-1,2-
25 ethanediamine (intermediate 22).

Example A.4

- a) A mixture of 6,7-dihydro-5*H*-cyclopenta[b]pyridin-7-ol (0.03544 mol), 3-hydroxy-4-methoxybenzaldehyde (0.0322 mol) and triphenylphosphine (0.0322 mol) in THF
30 (100 ml) was stirred at 5 °C under N₂ atmosphere. Bis(1-methylethyl) diazene-dicarboxylate (0.0322 mol) was added dropwise and the resulting reaction mixture was stirred for 12 hours at RT. The solvent was evaporated. CH₂Cl₂ was added to the residue. The mixture was washed with water, dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent: CH₂Cl₂/CH₃OH from 100/0 to 98.5/1.5). The desired fractions were collected and the solvent
35 was evaporated. The residue was dissolved in 2-propanol and converted into the hydrochloric acid salt (1:1) with HCl/2-propanol. The solvent was evaporated. The residue

-21-

was stirred in DIPE, filtered off and dried, yielding 8.2 g (83%) of 3-[(5,6-dihydro-7H-pyridin-7-yl)oxy]-4-methoxybenzaldehyde hydrochloride (intermediate 34).

- b) A solution of trimethylsilanecarbonitrile, (0.1472 mol) in CH₂Cl₂ (60 ml) was added dropwise to a mixture of 3-[(2,3-dihydro-1H-inden-2-yl)oxy]-4-methoxy-benzaldehyde (0.1227 mol) and Zinc iodide (0.0061 mol) in CH₂Cl₂ (240 ml). The resulting reaction mixture was stirred for one hour at RT. The crude reaction mixture was washed with water and brine, then extracted with CH₂Cl₂. The separated organic layer was dried, filtered, and the solvent was evaporated. The residue was crystallized from DIPE. The precipitate was filtered off and dried, yielding 37.39 g (83%) of (±)-3-[(2,3-dihydro-1H-inden-2-yl)oxy]-4-methoxy-α-[(trimethylsilyl)oxy]benzeneacetonitrile (intermediate 29).
- c) Intermediate 29 (0.1116 mol) was dissolved in methanol. HCl (3 N, 25 ml) was added. The mixture was stirred for 5 minutes. Most of the solvent was evaporated and CH₂Cl₂ was added. The organic layer was separated, washed with a saturated aqueous NaHCO₃ solution, dried, filtered and the solvent was evaporated. The residue was dissolved in CH₂Cl₂ (350 ml). 3,4-dihydro-2H-pyran (0.2231 mol) and 4-methylbenzenesulfonic acid (catalytic quantity) were added and the resulting reaction mixture was stirred overnight at RT. The mixture was washed with a saturated aqueous NaHCO₃ solution, dried, filtered and the solvent was evaporated. The residue was purified by short open column chromatography over silica gel (eluent: hexanes/ethylacetate 9/1, then 8/2). The desired fractions were collected and the solvent was evaporated, yielding: 28.01 g (66%) of (±)-3-[(2,3-dihydro-1H-inden-2-yl)oxy]-4-methoxy-α-[(tetrahydro-2H-pyran-2-yl)oxy]benzeneacetonitrile (intermediate 30).

Example A.5

- a) A solution of bis(1,1-dimethylethyl) dicarbonoate (1.268 mol) in CH₂Cl₂ (1800 ml) was added dropwise to a solution of (±)-3-[(2,3-dihydro-1H-inden-2-yl)oxy]-4-methoxy-β-methylbenzeneethanamine (1.208 mol) in C (1800 ml). The mixture was stirred at RT for 2 hours. The solvent was evaporated. The residue was stirred in hexane, filtered off and dried, yielding 420 g of (±)-1,1-dimethylethyl [2-[3-[(2,3-dihydro-1H-inden-2-yl)oxy]-4-methoxyphenyl]propyl]carbamate (intermediate 31).
- b) Intermediate 31 (1.056 mol) was purified and separated by chiral column chromatography over Chiralpack AD (eluent: hexane/C₂H₅OH/CH₃OH 90/10/10). The desired fraction group was collected and the solvent was evaporated, yielding 268 g 1,1-dimethylethyl B-[2-[3-[(2,3-dihydro-1H-inden-2-yl)oxy]-4-methoxyphenyl]-propyl]-carbamate (intermediate 32).
- c) A mixture of intermediate 32 (0.67 mol) in HCl (670ml; 6N) and methanol (2700ml) was stirred and refluxed for 90 minutes. The solvent was evaporated. The residue was

-22-

taken up in CH₂Cl₂. The organic solution was washed with H₂O (1000ml) and a saturated NaHCO₃ solution. The organic layer was separated, dried, filtered and the solvent was evaporated, yielding 158g (99%) of (B)-3-[(2,3-dihydro-1*H*-inden-2-yl)oxy]-4-methoxy-β-methylbenzeneethanamine (intermediate 33).

- 5 Intermediate 33 was further reacted according to the procedure described in example A.2.b to A.2.d to form (B)-*N*''-cyano-*N*-[2-[3-[(2,3-dihydro-1*H*-inden-2-yl)oxy]-4-methoxyphenyl]propyl]-*N*'-(2,2-dimethoxyethyl)guanidine (intermediate 26).

B. Preparation of the compounds of formula (I)

10 Example B.1

A mixture of intermediate 22 (0.0068 mol) and dimethyl cyanocarbonimidodithioate (0.0068 mol) in ethanol (20 ml) was stirred and refluxed for 2 days. The solvent was evaporated and the residue was first purified by short open column chromatography over silica gel (eluent: CH₂Cl₂, CH₂Cl₂/CH₃OH 96/4 and 90/10), then twice by HPLC
15 (1 eluent: CH₂Cl₂/CH₃OH 90/10 and 2. Eluent: CH₂Cl₂/CH₃OH 96/4). The pure fractions were collected and the solvent was evaporated, yielding 0.3 g (13%) of (±)-[1-[2-[3-(cyclopentyloxy)-4-methoxyphenyl]propyl]-2-imidazolidinylidene]-cyanamide (compound 1).

Example B.2

- 20 HCl 0.5 N (0.0162 mol) was added dropwise to a solution of intermediate 12 (0.0108 mol) in 1,4-dioxane (20 ml), stirred and cooled in an ice-bath. The reaction mixture was stirred for 2 days at RT. (As an alternative, 1,4-dioxane may be replaced by THF and the reaction mixture may be refluxed for 1 hour instead of stirring 2 days at RT). The reaction mixture was treated with water, alkalized with a dilute NaOH solution,
25 then extracted with ethylacetate. The separated organic layer was dried, filtered, and the solvent was evaporated. The residue was purified by open column chromatography over silica gel (eluent: CH₂Cl₂/2-propanone 96/4; CH₂Cl₂/CH₃OH 96/4) and twice by HPLC over silica gel (1. Eluent: CH₂Cl₂/CH₃OH 96/4 and 2. Eluent: CH₂Cl₂/CH₃OH 97/3). The pure fractions were collected and the solvent was evaporated, yielding
30 0.64 g (15%) of (±)-[1-[2-[4-(difluoromethoxy)-3-[(tetrahydro-3-furanyl)oxy]phenyl]-propyl]-1,3-dihydro-2*H*-imidazol-2-ylidene]cyanamide (compound 2; mp. 67.8 °C).

Example B.3

- a) Compound 7 (0.00644 mol) was separated into its enantiomers by chiral column chromatography over Chiralpak AD (20 μm, 250 g, 5 cm, flow: 60 ml/min; eluent:
35 hexane/ethanol/methanol 80/15/5). Two desired fraction groups were collected. The solvent of the first (A)-fraction group was evaporated. The residue was stirred in DIPE, filtered off, washed with DIPE, then dried. The residue was further purified by column

-23-

chromatography over Kromasil silica gel (200 g, 5 μ m, eluent: CH₂Cl₂/CH₃OH 100/0, after 30 minutes, 90/10). The pure fractions were collected and the solvent was evaporated. The residue was stirred in DIPE, filtered off, washed with DIPE, then dried, yielding 0.39 g (50%) of (+)-(A)-[1-[2-[3-[(2,3-dihydro-1*H*-inden-2-yl)oxy]-4-methoxy-phenyl]-propyl]-1*H*-imidazol-2-yl]cyanamide; $[\alpha]_D^{20} = +95.46^\circ$ (c = 0.1 % in CH₃OH) (compound 16).

The solvent of the second (B)-fraction group was evaporated. The residue was stirred in DIPE, filtered off, washed with DIPE, then dried. The residue was purified by column chromatography over Kromasil silica gel (200 g, 5 μ m, eluent: CH₂Cl₂/CH₃OH 100/0, after 30 minutes, 90/10). The pure fractions were collected and the solvent was evaporated. The residue was stirred in DIPE, filtered off, washed with DIPE, then dried, yielding 0.5 g (90%) of (-)-(B)-[1-[2-[3-[(2,3-dihydro-1*H*-inden-2-yl)oxy]-4-methoxy-phenyl]propyl]-1*H*-imidazol-2-yl]cyanamide; $[\alpha]_D^{20} = -109.04^\circ$ (c = 0.1 % in CH₃OH) (compound 17).


b) A mixture of compound 17 (0.0026 mol) in DMF (40 ml) was stirred at 0 °C. Sodium hydride (0.0028 mol; 60 %) was added and the mixture was stirred for 30 minutes at 0 °C and for 30 minutes at RT. A solution of bromomethylbenzene (0.0028 mol) in DMF (10 ml) was added dropwise and the resulting reaction mixture was stirred for 3 hours at RT. The solvent was evaporated, toluene was added and azeotroped on the rotary evaporator. The residue was taken up into CH₂Cl₂. Water was added. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by short column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 98/2). The desired fractions were collected and the solvent was evaporated, yielding 0.7 g (63%) of (B)-[1-[2-[3-[(2,3-dihydro-1*H*-inden-2-yl)oxy]-4-methoxy-phenyl]propyl]-3-phenylmethyl-1*H*-imidazol-2-yl]cyanamide (compound 23).

Example B.4






HCl (0.0268 mol; 0.5N) was added to a solution of intermediate 28 (0.0179 mol) in THF (250 ml), stirred and cooled on an ice-bath. The reaction mixture was stirred and refluxed for 1.5 hours, then cooled on an ice-bath. The mixture was partitioned between water and ethylacetate, and alkalized with solid Na₂CO₃. The organic layer was separated, dried, filtered, and the solvent was evaporated. The residue was purified by short open column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 97/3, then 95/5). The desired pure fraction group was collected. The solvent was evaporated and the residue was crystallized from CH₃CN, filtered off and dried, yielding (35%) of (±)-[1-[2-[3-[(2,3-dihydro-1*H*-inden-2-yl)oxy]-4-methoxyphenyl]-2-hydroxyethyl]-1,3-dihydro-2*H*-imidazol-2-ylidene]cyanamide (compound 21).






Table 1 lists compounds of formula (I) that were prepared according to one of the above examples.

Table 1



5

Co. No.	Ex. No.	R ¹	R ²	R ⁴	L	-A-B-	Physical data mp in °C
1	B.1	cyclopentyl	CH ₃	CH ₃	H	-CH ₂ -CH ₂ -	(E+Z)
2	B.2	3-tetrahydrofuranyl	CHF ₂	CH ₃	H	-CH=CH-	67.8 °C
3	B.2	cyclopentyl	CH ₃	CH ₃	H	-CH=CH-	101.3 °C
4	B.2	cyclopentyl	CHF ₂	CH ₃	H	-CH=CH-	133 °C
5	B.2	cyclopentyl	CHF ₂	H	H	-CH=CH-	158.9 °C
6	B.2	cyclopropylmethyl	CHF ₂	CH ₃	H	-CH=CH-	liquid
7	B.2		CH ₃	CH ₃	H	-CH=CH-	87.5 °C
8	B.2	cyclopropylmethyl	CH ₃	CH ₃	H	-CH=CH-	66.2 °C
9	B.2	phenylpentyl	CH ₃	CH ₃	H	-CH=CH-	-
10	B.2	3-tetrahydrofuranyl	CH ₃	CH ₃	H	-CH=CH-	73.4 °C
11	B.2	phenylpentyl	CHF ₂	CH ₃	H	-CH=CH-	-
12	B.3	cyclopentyl	CH ₃	CH ₃	H	-CH=CH-	(A)
13	B.3	cyclopentyl	CH ₃	CH ₃	H	-CH=CH-	(B)
14	B.3	cyclopropylmethyl	CH ₃	CH ₃	H	-CH=CH-	(A)
15	B.3	cyclopropylmethyl	CH ₃	CH ₃	H	-CH=CH-	(B)
16	B.3		CH ₃	CH ₃	H	-CH=CH-	(A)
17	B.2 or B.3		CH ₃	CH ₃	H	-CH=CH-	(B); 138.7 °C
18	B.3	phenylpentyl	CH ₃	CH ₃	H	-CH=CH-	(A)
19	B.3	phenylpentyl	CH ₃	CH ₃	H	-CH=CH-	(B)
20	B.2		CH ₃	H	H	-CH=CH-	-
21	B.4		CH ₃	OH	H	-CH=CH-	mp. 179.9 °C

Co. No.	Ex. No.	R ¹	R ²	R ⁴	L	-A-B-	Physical data mp in °C
22	B.2		CH ₃	CH ₃	H	-CH=CH-	mp. 115.3°C
23	B.3b		CH ₃	CH ₃	phenylmethyl	-CH=CH-	(B)
24	B.3b		CH ₃	CH ₃	C(=O)OC ₂ H ₅	-CH=CH-	(B)
25	B.3b		CH ₃	CH ₃	diphenylmethyl	-CH=CH-	(B)
26	B.2		CH ₃	H	H	-CH=CH-	-

C. Pharmacological example

Example C.1: Inhibition of recombinant human mononuclear lymphocyte (MNL)

5 phosphodiesterase type IV B produced in insect cells with a baculovirus vector.

The alleviating and/or curing effect of the instant compounds on allergic and atopic diseases was assessed by an *in vitro* assay system to detect an inhibiting effect on the recombinant human MNL phosphodiesterase type IV B.

- 10 Seventy-two hours after infection with recombinant baculovirus, the insect cells were harvested and pelleted at 500 g for 5 minutes. The cells were lysed in 10 ml lysis-buffer consisting of 20 mM Tris, 10 mM EGTA, 2 mM Na₂EDTA, 1% Triton-X-100, 1mM Na₃VO₄, 10 mM NaF, 2 µg/ml of leupeptine, pepstatine and aprotinine, 0.3 µg/ml benzamidine and 100 µg/ml TPCK pH 7.5. After 5 minutes on ice,
- 15 solubilized cells were centrifuged at 4000 rpm for 15 minutes at 4°C. The resulting supernatant was filtered through a 0.45 µm filter (Millipore) and brought to TBS buffer (50 mM Tris, 150 mM NaCl pH 7.4).

- The supernatant containing phosphodiesterase (PDE) type IV B, was subsequently
- 20 loaded onto a 5 ml anti-FLAG-M₂ affinity gel column, previously activated with 5 ml 100 mM glycine pH 3.5 and equilibrated with 20 ml 50 mM Tris, 150 mM NaCl pH 7.4. After washing the column with equilibration buffer, PDE IV was eluted in 1.5 ml fractions containing 37.5 µl 1M Tris pH 8. The fractions were dialyzed overnight against 20 mM Tris, 2mM Na₂EDTA and 400 mM NaCl pH 7.5 and tested for PDE IV
- 25 activity. Identification was done on SDS PAGE and Western Blot (anti-FLAG-M₂). Active fractions were pooled, brought to 10% glycerol and stored at -70°C.

-26-

The incubation mixture (pH 8) (200 μ l) contained 20 mM Tris, 10 mM magnesium sulphate, 0.8 μ M 3 H-cAMP (310 mCi/mmol) and the phosphodiesterase type IV, the amount depending on the enzymatic activity. A protein concentration was chosen that showed a linear increase of phosphodiesterase activity during an incubation period of maximum 10 minutes at 37°C and where less than 10% of the initial substrate was hydrolyzed.

When the effect of different compounds on phosphodiesterase activity was tested, the medium without cAMP was incubated with the compound(s) or its carrier (DMSO - 1% final concentration) for 5 minutes. The enzymatic reaction was started by addition of 3 H-cAMP and stopped 10 minutes later after transferring the microtiter-plate in a waterbath at 100°C for 5 minutes. After cooling to room temperature, alkaline phosphatase (0.25 μ g/ml) was added and the mixture was incubated at 37°C for 20 min. 100 μ l of the mixture was subsequently applied to a GF-B filter-microtiter-plate (Millipore) filled with 300 μ l DEAE-Sephadex-A25 suspension. The plate was washed 3 times with 75 μ l 20 mM Tris pH 7.5 and the filtrates were collected for counting in the Packard Top Count scintillation counter.

The inhibiting effect of the present compounds on recombinant human MNL phosphodiesterase PDE IV B was measured at different concentrations of the instant compounds. The IC₅₀ values (expressed in M) were calculated graphically from the thus obtained inhibition values and are listed in Table 2.

Table 2

Comp. No.	IC ₅₀ (in 10 ⁻⁸ M)
1	33.0
2	10.0
3	3.00
4	1.53
5	2.66
6	2.24
7	1.90
8	5.65
9	3.61
10	19.6

Comp. No.	IC ₅₀ (in 10 ⁻⁸ M)
11	3.27
12	2.19
13	2.22
14	2.72
15	3.35
16	1.80
17	3.00
18	4.09
19	3.75
20	7.65

25

D. Composition examples

The following formulations exemplify typical pharmaceutical compositions suitable for systemic or topical administration to animal and human subjects in accordance with the present invention.

"Active ingredient" (A.I.) as used throughout these examples relates to a compound of formula (I) or a pharmaceutically acceptable addition salt thereof.

Example D.1 : film-coated tablets

Preparation of tablet core

A mixture of 100 g of the A.I., 570 g lactose and 200 g starch was mixed well and thereafter humidified with a solution of 5 g sodium dodecyl sulfate and 10 g polyvinylpyrrolidone in about 200 ml of water. The wet powder mixture was sieved, dried and sieved again. Then there was added 100 g microcrystalline cellulose and 15 g hydrogenated vegetable oil. The whole was mixed well and compressed into tablets, giving 10.000 tablets, each comprising 10 mg of the active ingredient.

Coating


To a solution of 10 g methyl cellulose in 75 ml of denaturated ethanol there was added a solution of 5 g of ethyl cellulose in 150 ml of dichloromethane. Then there were added 75 ml of dichloromethane and 2.5 ml 1,2,3-propanetriol. 10 g of polyethylene glycol was molten and dissolved in 75 ml of dichloromethane. The latter solution was added to the former and then there were added 2.5 g of magnesium octadecanoate, 5 g of polyvinylpyrrolidone and 30 ml of concentrated color suspension and the whole was homogenated. The tablet cores were coated with the thus obtained mixture in a coating apparatus.

Example D.2 : 2% topical cream

To a solution of 200 mg hydroxypropyl β -cyclodextrine in purified water is added 20 mg of A.I. while stirring. Hydrochloric acid is added until complete dissolution and next sodium hydroxide is added until pH 6.0. While stirring, 50 mg glycerol and 35 mg polysorbate 60 are added and the mixture is heated to 70°C. The resulting mixture is added to a mixture of 100 mg mineral oil, 20 mg stearyl alcohol, 20 mg cetyl alcohol, 20 mg glycerol monostearate and 15 mg sorbate 60 having a temperature of 70°C while mixing slowly. After cooling down to below 25°C, the rest of the purified water q.s. ad 1 g is added and the mixture is mixed to homogenous.

Claims

1. A compound having the formula



a *N*-oxide form, a pharmaceutically acceptable acid or base addition salt or a stereochemically isomeric form thereof, wherein :

- 5 R^1 and R^2 each independently are hydrogen; C_{1-6} alkyl; difluoromethyl; trifluoromethyl; C_{3-6} cycloalkyl; a saturated 5-, 6- or 7-membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur or nitrogen; indanyl; 6,7-dihydro-5*H*-cyclopentapyridinyl; bicyclo[2.2.1]-2-heptenyl;
- 10 bicyclo[2.2.1]heptanyl; C_{1-6} alkylsulfonyl; arylsulfonyl; or C_{1-10} alkyl substituted with one or two substituents each independently selected from aryl, pyridinyl, thienyl, furanyl, indanyl, 6,7-dihydro-5*H*-cyclopentapyridinyl, C_{3-7} cycloalkyl and a saturated 5-, 6- or 7-membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur or nitrogen;
- 15 R^3 is hydrogen, halo or C_{1-6} alkyloxy;
- R^4 is hydrogen; halo; C_{1-6} alkyl; trifluoromethyl; C_{3-6} cycloalkyl; carboxyl; C_{1-4} alkyloxycarbonyl; C_{3-6} cycloalkylaminocarbonyl; aryl; Het¹; or C_{1-6} alkyl substituted with cyano, amino, hydroxy, C_{1-4} alkylcarbonylamino, aryl or Het¹; or
- R^4 is a radical of formula :
- 20 $-O-R^7$ (a-1); or
- $-NH-R^8$ (a-2);
- wherein R^7 is hydrogen; C_{1-6} alkyl; C_{1-6} alkyl substituted with hydroxy, carboxyl, C_{1-4} alkyloxycarbonyl, amino, mono- or di(C_{1-4} alkyl)amino, Het¹ or aryl;
- 25 R^8 is hydrogen; C_{1-6} alkyl; C_{1-4} alkylcarbonyl; C_{1-6} alkyl substituted with hydroxy, carboxyl, C_{1-4} alkyloxycarbonyl, amino, mono- or di(C_{1-4} alkyl)amino, Het¹ or aryl;
- R^5 is hydrogen, halo, hydroxy, C_{1-6} alkyl or C_{1-6} alkyloxy; or
- R^4 and R^5 taken together may form a bivalent radical of formula :
- 30 $-(CH_2)_n-$ (b-1);
- $-CH_2-CH_2-O-CH_2-CH_2-$ (b-2);
- $-CH_2-CH_2-N(R^9)-CH_2-CH_2-$ (b-3); or
- $-CH_2-CH=CH-CH_2-$ (b-4);

-29-

wherein n is 2, 3, 4 or 5;

R^9 is hydrogen, C_{1-6} alkyl, C_{1-6} alkylsulfonyl or *p*-toluenesulfonyl;

R^6 is a hydrogen or C_{1-4} alkyl; or

R^4 and R^6 taken together may form a bivalent radical of formula $-(CH_2)_m-$;

5 wherein m is 1, 2, 3 or 4;

-A-B- is a bivalent radical of formula :

$-CR^{10}=CR^{11}-$ (c-1); or

$-CHR^{10}-CHR^{11}-$ (c-2);

wherein each R^{10} and R^{11} independently is hydrogen or C_{1-4} alkyl; and

10 L is hydrogen; C_{1-6} alkyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyloxycarbonyl; C_{1-6} alkyl substituted with one or two substituents selected from the group consisting of hydroxy, C_{1-4} alkyloxy, C_{1-4} alkyloxycarbonyl, mono- and di(C_{1-4} alkyl)amino, aryl and Het²; C_{3-6} alkenyl; C_{3-6} alkenyl substituted with aryl; piperidinyl; piperidinyl substituted with C_{1-4} alkyl or aryl C_{1-4} alkyl; C_{1-6} alkylsulfonyl or arylsulfonyl;

15 aryl is phenyl or phenyl substituted with one, two or three substituents selected from halo, hydroxy, C_{1-4} alkyl, C_{1-4} alkyloxy, C_{3-6} cycloalkyl, trifluoromethyl, amino, nitro, carboxyl, C_{1-4} alkyloxycarbonyl and C_{1-4} alkylcarbonylamino;

Het¹ is pyridinyl; pyridinyl substituted with C_{1-4} alkyl; furanyl; furanyl substituted with C_{1-4} alkyl; thienyl; thienyl substituted with C_{1-4} alkylcarbonylamino;

20 hydroxypyridinyl, hydroxypyridinyl substituted with C_{1-4} alkyl or C_{1-4} alkoxy- C_{1-4} alkyl; imidazolyl; imidazolyl substituted with C_{1-4} alkyl; thiazolyl; thiazolyl substituted with C_{1-4} alkyl; oxazolyl; oxazolyl substituted with C_{1-4} alkyl;

25 isoquinolinyl; isoquinolinyl substituted with C_{1-4} alkyl; quinolinonyl, quinolinonyl substituted with C_{1-4} alkyl; morpholinyl; piperidinyl; piperidinyl substituted with C_{1-4} alkyl, C_{1-4} alkyloxycarbonyl or aryl C_{1-4} alkyl; piperazinyl; piperazinyl substituted with C_{1-4} alkyl, C_{1-4} alkyloxycarbonyl or aryl C_{1-4} alkyl; and

Het² is morpholinyl; piperidinyl; piperidinyl substituted with C_{1-4} alkyl or aryl C_{1-4} alkyl; piperazinyl; piperazinyl substituted with C_{1-4} alkyl or

30 aryl C_{1-4} alkyl; pyridinyl; pyridinyl substituted with C_{1-4} alkyl; furanyl; furanyl substituted with C_{1-4} alkyl; thienyl or thienyl substituted with C_{1-4} alkyl or C_{1-4} alkylcarbonylamino.

2. A compound according to claim 1 wherein R^1 and R^2 each independently are
35 hydrogen; C_{1-6} alkyl; difluoromethyl; trifluoromethyl; C_{3-6} cycloalkyl; a saturated 5-, 6- or 7-membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur or nitrogen; indanyl; bicyclo[2.2.1]-2-heptenyl;

-30-

bicyclo[2.2.1]heptanyl; C₁₋₆alkylsulfonyl; arylsulfonyl; or C₁₋₁₀alkyl substituted with one or two substituents each independently selected from aryl, pyridinyl, thienyl, furanyl, C₃₋₇cycloalkyl and a saturated 5-, 6- or 7-membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur or nitrogen.

5

3. A compound according to claim 1 or 2 wherein R¹ and R² are each independently C₁₋₆alkyl; C₃₋₆cycloalkyl; difluoromethyl; a saturated 5-, 6- or 7-membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur or nitrogen; indanyl; or C₁₋₁₀alkyl substituted with aryl, indanyl, 6,7-dihydro-5H-cyclopentapyridinyl or C₃₋₆cycloalkyl.
4. A compound according to any one of claims 1 to 3 wherein R⁴ is C₁₋₆alkyl.
5. A compound according to any one of claims 1 to 4 wherein R¹ is cyclopentyl, tetrahydrofuranyl, cyclopropylmethyl, 5-phenylpentyl, 6,7-dihydro-5H-cyclopenta[b]pyridinyl or indanyl; R² is methyl or difluoromethyl; and R³, R⁵, R⁶, R¹⁰, R¹¹ and L are hydrogen.
6. A compound according to claim 1 wherein the compound is
[1-[2-[4-(difluoromethoxy)-3-[(tetrahydro-3-furanyl)oxy]phenyl]propyl]-1,3-dihydro-2H-imidazol-2-ylidene]cyanamide; and
[1-[2-[4-(methoxy)-3-[(1,3-dihydro-2H-inden-2-yl)oxy]phenyl]propyl]-1,3-dihydro-2H-imidazol-2-ylidene]cyanamide, or a N-oxide, a stereochemically isomeric form or a pharmaceutically acceptable additon salt thereof.
7. A composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as claimed in any one of claims 1 to 6.
8. A process of preparing a composition as claimed in claim 7, characterized in that a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as claimed in any one claims 1 to 6.
9. A compound as claimed in any one of claims 1 to 6 for use as a medicine.
10. The use of a compound as claimed in any one of claims 1 to 6 in the manufacture of a medicament useful for treating atopic or asthmatic diseases.
11. A process of preparing a compound as claimed in claim 1, characterized by

10

15

20


25

30

35


-31-

- a) cyclization of an intermediate of formula (II) or a functional derivative thereof wherein R^1 to R^6 , R^{10} and R^{11} are defined as in claim 1,




in a reaction inert solvent and in the presence of a suitable acid; thus forming a compound of formula (I-a-1);

- b) cyclization of an intermediate of formula (II-1) wherein R^1 to R^4 , R^6 , R^{10} and R^{11} are defined as in claim 1 and P is hydrogen or a trimethylsilyl protecting group or a functional derivative thereof,



in a reaction inert solvent and in the presence of a suitable acid; thus forming a compound formula (I-a-1-1);

- c) cyclization of an intermediate of formula (III) or a functional derivative thereof wherein R^1 to R^6 , R^{10} and R^{11} are defined as in claim 1,




in a reaction inert solvent and in the presence of dimethyl

-32-

cyanocarbonimidodithioate or diphenyl *N*-cyanocarbonimidate, thus forming a compound of formula (I-a-2);

- 5 d) reacting an organometallic intermediate of formula (IV), wherein R^1 to R^3 are defined as in claim 1 and M is an appropriate metal ion or metalcomplex ion,



in a reaction-inert solvent with a suitable 2-cyanoiminoimidazole derivative of formula (V) wherein R^4 to R^6 , L and -A-B- are defined as in claim 1 and W^1 is a reactive leaving group;

10

and, if desired, converting compounds of formula (I) into each other following art-known transformations, and further, if desired, converting the compounds of formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or

15 conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and, if desired, preparing stereochemically isomeric forms or *N*-oxide forms thereof.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 97/05322

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C07D233/44 A61K31/415 C07D233/88		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 00218 A (EURO CELTIQUE SA ;CAVALLA DAVID (GB); CHASIN MARK (US); DOLBY LLOY) 4 January 1996 see the whole document ---	1-11
Y	WO 95 20578 A (RHONE POULENC RORER LTD ;FENTON GARRY (GB); PALFREYMAN MALCOLM NOR) 3 August 1995 see the whole document ---	1-11
Y	WO 94 12461 A (PFIZER ;DUPLANTIER ALLEN J (US); EGGLEER JAMES F (US); MARFAT ANTHO) 9 June 1994 see the whole document ---	1-11
-/-		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search 10 February 1998		Date of mailing of the international search report 27. 02.98
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Stellmach, J

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 97/05322

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 94 02465 A (RHONE POULENC RORER LTD ;FENTON GARRY (GB); MORLEY ANDREW DAVID (G) 3 February 1994 see the whole document ---	1-11
Y	WO 95 04045 A (RHONE POULENC RORER LTD ;FENTON GARRY (GB); MAJID TAHIR NADEEM (GB) 9 February 1995 see the whole document ---	1-11
Y	WO 95 05386 A (SMITHKLINE BEECHAM CORP ;CHRISTENSEN SIEGFRIED B (US); FORSTER COR) 23 February 1995 cited in the application see the whole document ---	1-11
Y	WO 94 20455 A (CELLTECH LTD) 15 September 1994 see the whole document ---	1-11
X,P	WO 96 31485 A (JANSSEN PHARMACEUTICA NV ;FREYNE EDDY JEAN EDGARD (BE); DIELS GAST) 10 October 1996 see the whole document ---	1-11
X,P	WO 96 31486 A (JANSSEN PHARMACEUTICA NV ;FREYNE EDDY JEAN EDGARD (BE); DIELS GAST) 10 October 1996 see the whole document ---	1-11
X,P	WO 96 31487 A (JANSSEN PHARMACEUTICA NV ;FREYNE EDDY JEAN EDGARD (BE); DIELS GAST) 10 October 1996 see the whole document -----	1-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/05322

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9600218 A	04-01-96	AU 3070695 A	19-01-96
		CA 2193725 A	04-01-96
		EP 0766676 A	09-04-97
		US 5591776 A	07-01-97
		ZA 9505274 A	02-02-96

WO 9520578 A	03-08-95	AU 1463195 A	15-08-95
		EP 0741707 A	13-11-96
		JP 9509654 T	30-09-97
		ZA 9500639 A	26-07-96

WO 9412461 A	09-06-94	AU 673569 B	14-11-96
		AU 5539694 A	22-06-94
		CA 2150812 A	09-06-94
		CN 1094028 A	26-10-94
		CZ 9501417 A	15-11-95
		EP 0672031 A	20-09-95
		FI 935379 A	03-06-94
		HU 65928 A	28-07-94
		IL 107758 A	20-11-97
		JP 8501318 T	13-02-96
		NO 952178 A	01-08-95
		NZ 257955 A	28-05-96
		PL 309257 A	02-10-95
		ZA 9308978 A	01-06-95

WO 9402465 A	03-02-94	AU 4717693 A	14-02-94
		CA 2140441 A	03-02-94
		CZ 9500147 A	17-07-96
		EP 0652868 A	17-05-95
		FI 950375 A	27-01-95
		HU 72656 A	28-05-96
		HU 211979 B	29-01-96
		JP 8503925 T	30-04-96
		MX 9304571 A	31-05-94
		NO 950319 A	27-03-95
		NZ 254881 A	25-09-96
		PL 307265 A	15-05-95
		US 5679696 A	21-10-97
		US 5698711 A	16-12-97

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internatio. Application No

PCT/EP 97/05322

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9402465 A		ZA 9305448 A	19-05-94
WO 9504045 A	09-02-95	AU 7267094 A	28-02-95
		CA 2160928 A	09-02-95
		EP 0711282 A	15-05-96
		JP 9501155 T	04-02-97
		ZA 9405609 A	12-05-95
WO 9505386 A	23-02-95	EP 0714397 A	05-06-96
		JP 9502170 T	04-03-97
WO 9420455 A	15-09-94	AT 157962 T	15-09-97
		AU 677294 B	17-04-97
		AU 6148894 A	26-09-94
		DE 69405497 D	16-10-97
		EP 0640070 A	01-03-95
		JP 8501801 T	27-02-96
		NZ 262169 A	27-07-97
		US 5633257 A	27-05-97
WO 9631485 A	10-10-96	AU 5275596 A	23-10-96
		EP 0819122 A	21-01-98
		HR 960155 A	31-10-97
		NO 974602 A	06-10-97
WO 9631486 A	10-10-96	AU 5275696 A	23-10-96
		EP 0819123 A	21-01-98
WO 9631487 A	10-10-96	AU 5497996 A	23-10-96